Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

June Health vs NuvaHealth

June Health
Graded #261

Lower grade

vs+11.200000000000003
NuvaHealth
Graded #65

Higher grade

The verdict

NuvaHealth takes it — 74.2/100 to 63/100.

NuvaHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuvaHealth (nuvahealth.org) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide starting at $159 first-month and compounded tirzepatide starting at $259 first-month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuvaHealth +15
61
76
Dose & formulationNuvaHealth +13
75
88
Clinical oversightNuvaHealth +23
59
82
Labs & monitoringNuvaHealth +2
51
53
FulfillmentEven
74
74
Contract termsEven
55
55
June Health · left barNuvaHealth · right bar

The numbers

MetricJune HealthNuvaHealth
WeighScore63/10074.2/100
GradeCC
Scorecard rank#261#65
Semaglutide$179/mo (starting dose, compounded)$139/mo (first-month rate, compounded)
Tirzepatide$179/mo (starting dose, compounded)$229/mo (first-month rate, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
June Health

Graded #261 · C

Strengths

  • Offers both injectable and oral compounded semaglutide and tirzepatide
  • Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
  • Full per-dose price list published on-site with no signup required to view it
  • Provider consult ('licensed clinician evaluation') is bundled into the displayed price
  • Free discreet shipping advertised with 2-3 day delivery

Where it loses points

  • No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
  • No LegitScript seal or other pharmacy-verification badge found anywhere on the site
  • Legal entity, prescribing medical group, and compounding pharmacy partner are not named
  • Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
  • Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use
NuvaHealth

Graded #65 · C

Strengths

  • LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
  • Free and fast delivery + 24/7 patient support disclosed on the home page
  • Newark, DE address suggests a US-incorporated entity (vs offshore)
  • $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
  • $229 first-month price for compounded tirzepatide injection sits in the lower-median range

Where it loses points

  • Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
  • Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
  • Pharmacy partners NOT publicly named — material YMYL transparency gap
  • Per-state availability NOT enumerated; verify your state ships before purchase
  • Lab work + coaching support NOT publicly disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard